Pharmacoepidemiological features of drug therapy for chronic pain syndrome associated with malignant neoplasms
An expert analysis of 2000 discharge/postmortem epicrises was carried out to study the pharmacoepidemiology of drug therapy for chronic pain syndrome (CPS) in patients with malignant neoplasms who lived in the Krasnoyarsk Region. Most cases showed the compliance of analgesic therapy for chronic pain syndrome in cancer patients with the current guidelines. The found shortcomings of pharmacotherapy for chronic pain syndrome require strategic, organizational, and methodical measures in each health care facility.